Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events

The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of ophthalmology 2006-08, Vol.142 (2), p.366-366
Hauptverfasser: Bhatt, D.L., Fox, K.A., Hacke, W., Berger, P.B., Black, H.R., Boden, W.E., Cacoub, P., Cohen, E.A., Creager, M.A., Easton, J.D., Flather, M.D., Haffner, S.M., Hamm, C.W., Hankey, G.J., Johnston, S.C., Mak, K.H., Mas, J.L., Montalescot, G., Pearson, T.A., Steg, P.G., Steinhubl, S.R., Weber, M.A., Brennan, D.M., Fabry-Ribaudo, L., Booth, J., Topol, E.J.
Format: Artikel
Sprache:eng
Schlagworte:
Aspirin
Confidence intervals
Drug therapy
Heart attacks
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The aim of the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) study was to evaluate dual antiplatelet therapy with clopidogrel plus low-dose aspirin in a broad population of patients at high risk for atherothrombotic events.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2006.06.024